Search company, investor...
Metabolon company logo


Founded Year



Series F - II | Alive

Total Raised


Last Raised

$25M | 3 days ago

About Metabolon

Metabolon is a health technology company that focuses on metabolomics. It offers a tool for precision medicine and life sciences research. The company offers metabolomics solutions for biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.

Headquarters Location

617 Davis Drive Suite 100

Morrisville, North Carolina, 27560,

United States


Missing: Metabolon's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Metabolon

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Medical Devices Tech

Companies in this market work to advance in-vitro testing methods, or tests performed on samples that have been removed from the body. Some companies develop — and in some cases perform — in-vitro tests to aid in clinical diagnosis and provide personalized health information and monitoring. Others design analytical instruments used for in-vitro testing.

Metabolon named as Leader among 9 other companies, including Tempus, Color, and Helix.

Missing: Metabolon's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metabolon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolon is included in 5 Expert Collections, including Omics.



1,542 items


Medical Devices

8,603 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

6,079 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Digital Health

13,119 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

Metabolon Patents

Metabolon has filed 68 patents.

The 3 most popular patent topics include:

  • Mass spectrometry
  • Analytical chemistry
  • Ion source
patents chart

Application Date

Grant Date


Related Topics




Hepatology, Diseases of liver, Metabolism, Mass spectrometry, Lithium compounds


Application Date


Grant Date



Related Topics

Hepatology, Diseases of liver, Metabolism, Mass spectrometry, Lithium compounds



Latest Metabolon News

08:07 ET Metabolon Secures $25 Million of Funding to Accelerate Growth

Jan 24, 2023

News provided by Share this article Share this article MORRISVILLE, N.C, Jan. 24, 2023 /CNW/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced that it has closed on $25 million of additional equity funding. The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap. "Metabolon is experiencing significant growth, and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand," said Rohan (Ro) Hastie, Metabolon's Chief Executive Officer. "Metabolomics is an essential component of the life science ecosystem. All omics approaches – genomics, proteomics, metabolomics – are highly complementary. You cannot fully understand biology, and more specifically systems biology, by just looking at DNA, proteins, or metabolites exclusively. As life sciences evolve toward a more sophisticated multi-omics approach, Metabolon is fast becoming an industry standard and a critical step toward true precision medicine." "This financing arrives on the heels of record revenue and margins in 2022 and comes predominantly from new investors, with additional participation by existing investors. The infusion of capital will allow us to continue accelerating our already robust growth and execution as we bring market-leading metabolomics and the associated deep phenotyping capabilities to a rapidly expanding market," said Gerry Haines, CFO of Metabolon. To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit . About Metabolon  Metabolon , Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research. Over 20 years, 10,000+ projects, over 3,000 publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is enabled by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit  and follow us on  LinkedIn  and  Twitter . About Metabolomics Metabolomics, the large-scale study of all small molecules in a biological system, is the only 'omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. SOURCE Metabolon, Inc.

Metabolon Frequently Asked Questions (FAQ)

  • When was Metabolon founded?

    Metabolon was founded in 2000.

  • Where is Metabolon's headquarters?

    Metabolon's headquarters is located at 617 Davis Drive, Morrisville.

  • What is Metabolon's latest funding round?

    Metabolon's latest funding round is Series F - II.

  • How much did Metabolon raise?

    Metabolon raised a total of $208M.

  • Who are the investors of Metabolon?

    Investors of Metabolon include Sevin Rosen Funds, Fletcher Spaght Ventures, Syngenta Ventures, EW Healthcare Partners, Perceptive Advisors and 10 more.

  • Who are Metabolon's competitors?

    Competitors of Metabolon include Inscripta, Qitan Technology, Vergent Bioscience, Tempus, MGI Tech, GenapSys, Sapient, Genemind Biosciences, Vizgen, Freenome and 48 more.

Compare Metabolon to Competitors

Nomic Bio Logo
Nomic Bio

Nomic Bio develops proteomic tools to better understand, detect, and treat disease.

Vergent Bioscience Logo
Vergent Bioscience

Vergent Bioscience offers a portfolio of molecular imaging products for the research and clinical community. Its platform uses peptide-based probes to provide in vivo assessment of underlying cell activity, including apoptosis, necrosis, and inflammation. The company serves clients in the healthcare sector. It was formerly known as Intracellular Technologies and In Vivo Technologies. The company was founded in 2013 and is based in Minneapolis, Minnesota.


SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.

Tempus Logo

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine-learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. The company was founded in 2015 and is based in Chicago, Illinois.

MOBILion Systems Logo
MOBILion Systems

MOBILion Systems develops structures for lossless ion manipulation (SLIM) as a platform technology for lossless ion transfer, manipulation, and ion mobility separations.

Vizgen Logo

Vizgen is developing the next generation of spatially resolved genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. MERFISH provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.